Pds biotech provides business update and reports fourth-quarter and full-year 2022 financial results

Florham park, n.j., march 28, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today provided a business update and announced its financial results for the year ended december 31, 2022.
PDSB Ratings Summary
PDSB Quant Ranking